Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Translational Research Program (TRP)
Contact CIP
Show menu
Search this site
Last Updated: 02/21/20

Hyperactive RAS SPOREs

Tumorigenesis has been viewed as a process in which normal developmental programs are dysregulated, leading to aberrant cellular proliferation and differentiation. These processes lead to a failure to respect normal tissue boundaries and abnormal response to multiple inhibitory microenvironmental cues. The RASopathies are developmental syndromes caused by mutations in various genes capable of altering the function of RAS family proteins and Mitogen-activated protein kinases (MAPKs) that control intracellular signal transduction. Neurofibromatosis type 1 (NF1) is the most frequent RASopathy syndrome that occurs in one in every 3000-4000 live births. This syndrome is caused by mutations of the NF1 tumor suppressor gene that functions as a GTPse activating protein for p21RAS. Individuals with NF1 have a high predisposition to plexiform neurofibromas, a premalignant tumor that causes major morbidity and mortality with life expectancy reduced by 8-15 years.

The Developmental and Hyperactive RAS Tumor SPORE (DHAR Tumor SPORE) focuses on devising better treatment for cancers and pre-malignant conditions associated with NF1 mutations including plexiform neurofibroma (pNF), malignant peripheral nerve sheath tumors (MPNST), juvenile myelomonocytic leukemia (JMML), and subsequent malignant neoplasms (SMN) in NF1 patients receiving radiation and chemotherapy for primary tumors.